GNPX Genprex, Inc. Stock Quote

GNPX [NASD]

Index	-	P/E	-	EPS (ttm)	-0.53	Insider Own	17.55%	Shs Outstand	39.06M	Perf Week	-0.53%
Market Cap	166.13M	Forward P/E	-	EPS next Y	-3.68	Insider Trans	0.00%	Shs Float	35.50M	Perf Month	11.28%
Income	-15.10M	PEG	-	EPS next Q	-0.28	Inst Own	23.40%	Short Float	8.90%	Perf Quarter	3.59%
Sales	-	P/S	-	EPS this Y	26.00%	Inst Trans	43.29%	Short Ratio	2.75	Perf Half Y	22.95%
Book/sh	0.59	P/B	6.36	EPS next Y	-569.10%	ROA	-79.40%	Target Price	-	Perf Year	941.67%
Cash/sh	0.48	P/C	7.87	EPS next 5Y	-	ROE	-81.30%	52W Range	0.33 - 7.03	Perf YTD	-9.64%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-46.66%	Beta	-
Dividend %	-	Quick Ratio	58.60	Sales past 5Y	-	Gross Margin	-	52W Low	1045.04%	ATR	0.34
Employees	8	Current Ratio	60.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	47.22	Volatility	6.63% 10.99%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	52.70%	Profit Margin	-	Rel Volume	0.81	Prev Close	3.83
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	1.15M	Price	3.75
Recom	2.00	SMA20	-8.73%	SMA50	4.75%	SMA200	12.96%	Volume	926,244	Change	-2.09%

Apr-29-19

Initiated

Noble Capital Markets

Outperform

Jan-14-21 08:30AM	Genprex to Present at NobleCon17 on January 19 Business Wire
Jan-13-21 09:00AM	Genprex Achieves Major Manufacturing Milestone for REQORSA Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer Business Wire
Dec-24-20 01:02PM	Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants Business Wire -14.88%
Dec-23-20 12:40PM	Let's Look at the Big Picture of Genprex TheStreet.com +23.27%
Dec-22-20 01:15PM	Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants Business Wire +12.31%
12:10PM	Genprex's Leading Drug Candidate Is Currently Being Developed As A Treatment For Lung Cancer Benzinga
09:32AM	Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer Business Wire
Dec-17-20 08:47AM	Genprex (GNPX) Looks Good: Stock Adds 6.5% in Session Zacks
Dec-08-20 08:16AM	Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy Business Wire
Dec-03-20 08:17AM	Genprex to Present at the Benzinga Global Small Cap Conference on December 8 Business Wire
Nov-30-20 02:05PM	Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer Business Wire
Nov-24-20 09:30AM	Diamond Equity Research 2020 Virtual Emerging Growth Invitational ACCESSWIRE
08:16AM	Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1 Business Wire
Nov-11-20 08:16AM	Genprex to Participate in Panel at Life Sciences Summit on November 17 Business Wire
Nov-10-20 08:17AM	Genprex Strengthens Scientific Advisory Board with Appointment of Lead Researcher of University of Pittsburgh, George K. Gittes, MD Business Wire
Oct-30-20 08:17AM	Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer Business Wire -7.93%
Oct-29-20 08:16AM	Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer Business Wire +14.24%
Oct-26-20 08:16AM	Genprex Promotes Eric Chapdelaine to Vice President of Manufacturing Business Wire
Oct-07-20 08:17AM	Genprex to Present at Zooming with LD Micro on October 14, 2020 Business Wire +5.40%
Oct-06-20 08:16AM	Genprex to Present at the Alliance for Regenerative Medicines Virtual Cell and Gene Meeting on the Mesa Business Wire
Sep-21-20 08:17AM	Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing Business Wire -5.00%
Sep-09-20 04:25PM	This Biotech Appears to Have the Right Formula for Investors TheStreet.com
Sep-02-20 05:36PM	LD Micro 360 Companies Set to Present this Week. ACCESSWIRE
08:17AM	Genprex Appoints William E. Gannon, Jr., MD, MBA, as Vice President of Regulatory Affairs Business Wire
Aug-26-20 08:17AM	Genprex to Present at The LD 500 Virtual Conference Business Wire -6.31%
08:17AM	Genprex to Present at The LD 500 Virtual Conference ACCESSWIRE
Aug-05-20 03:34PM	LD Micro-Announces Preliminary List of Presenters for the LD 500. ACCESSWIRE
Jul-31-20 08:17AM	Genprex to Present at Proactives One2One Virtual Investor Forum on August 4, 2020 Business Wire
Jul-30-20 08:16AM	Genprex CEO Participates in a Second-Round Live Interview on the "Big Biz Show" Business Wire
Jul-21-20 12:58PM	Sometimes, Stories Do Come True TheStreet.com +10.00%
08:17AM	National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex Business Wire
Jun-29-20 08:16AM	Genprex Added to Russell 3000® Index Business Wire
Jun-25-20 08:17AM	Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate Business Wire
Jun-24-20 08:16AM	Genprex CEO to Interview Live on "The Big Biz Show" Business Wire +17.42%
Jun-16-20 08:17AM	Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex Clinical Development Business Wire
Jun-09-20 08:17AM	Genprex Scheduled to Join Russell 3000® Index Business Wire +9.80%
Jun-08-20 08:17AM	Genprex to Present at the MoneyShow June Virtual Event Business Wire
May-28-20 08:17AM	Genprex Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises Business Wire
May-05-20 01:00PM	Genprex Is Soaring - And There's a One Word Reason Why TheStreet.com +51.52%
08:17AM	Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combination of its TUSC2 Gene Therapy with Immunotherapies Business Wire
May-04-20 08:17AM	Genprex Issues April 2020 Shareholder Letter Business Wire
Apr-21-20 08:17AM	Genprex Appoints Shannon Inman as Vice President of Global Clinical Operations Business Wire
Mar-24-20 08:17AM	Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry Leaders Business Wire +27.31%
Mar-23-20 08:17AM	Genprex Strengthens Leadership Team with the Appointment of Two Accomplished Life Science Executives Business Wire -9.56%
Mar-05-20 08:05AM	Lead Researcher Behind Genprexs Diabetes Gene Therapy Featured in New Video Interview Business Wire -7.30%
Mar-04-20 08:00AM	Genprex to Present at the 2020 LD Micro Virtual Conference ACCESSWIRE
Mar-03-20 08:17AM	Genprex to Present at the 2020 LD Micro Virtual Conference Business Wire -7.13%
Feb-21-20 04:15PM	Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants Business Wire +21.69%
Feb-20-20 10:22AM	Those Golden Rule TheStreet.com +12.31%
Feb-19-20 09:23AM	Genprex, Inc. Prices $17,500,000 Common Stock Offering Priced At-The-Market and Without Warrants Business Wire -20.41%
08:05AM	Benzinga Pro's Top 5 Stocks To Watch For Wed., Feb. 19, 2020: BLPH, GRPN, VIVE, CODX, GNPX Benzinga
Feb-11-20 08:17AM	Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes Business Wire +29.84%
Feb-06-20 08:17AM	Genprex Regains Compliance with Nasdaq Minimum Bid Price Requirement Business Wire -6.99%
Feb-05-20 09:00AM	Genprex to Focus Its Clinical Efforts on Oncoprex in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC) Business Wire
Feb-03-20 08:17AM	Genprex to Present at NobleCon16 Investor Conference Business Wire -7.18%
Jan-29-20 08:18AM	Independent Researchers Find Genprexs TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy Business Wire +23.44%
Jan-28-20 08:00AM	Genprex, Inc. Announces Closing of $8 Million At-The-Market Common Stock Offering Business Wire
Jan-24-20 07:00AM	Genprex: The Bad and the Good of Capital Raises TheStreet.com -8.57%
Jan-23-20 09:00AM	Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market Business Wire -25.93%
Jan-22-20 10:54AM	Genprex's stock rallies on FDA fast-track designation MarketWatch +64.35%
Jan-21-20 08:00AM	Genprex Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer Business Wire +219.44%
Jan-06-20 08:00AM	Genprex to Present at Biotech Showcase 2020 in San Francisco Business Wire +7.44%
Nov-20-19 11:15AM	Genprex Announces $1.26 Million Registered Direct Offering Business Wire -43.55%
Nov-19-19 08:00AM	Genprex Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung Cancers Business Wire +60.29%
Nov-04-19 08:00AM	Genprex Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month Business Wire
Oct-15-19 08:00AM	MicroCap Rodeo Investor Conference Lineup for October 15 and 16, 2019 ACCESSWIRE
Oct-09-19 08:00AM	Genprex to Present at the MicroCap Rodeo Investor Conference Business Wire -6.86%
Oct-07-19 08:00AM	Genprexs Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry Support Business Wire -8.00%
Sep-26-19 08:30AM	Genprex (GNPX) Featured in Audio Publication Discussing New Research on Breast Cancer Treatment GlobeNewswire
Sep-25-19 08:30AM	Genprex (GNPX) Featured in Publication on Advances in Potential Breast Cancer Treatments GlobeNewswire
Sep-18-19 08:00AM	Genprex to Present Via Webcast at the Singular Research Midwestern Values Conference on September 19, 2019 Business Wire
Sep-11-19 08:00AM	Independent Researchers Find Genprexs TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer Business Wire
Sep-07-19 04:35PM	CORRECTING and REPLACING Genprex to Present at the H.C. Wainwright 21st Annual Global Investment Conference Business Wire
Sep-06-19 08:30AM	Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Lung Cancer and Gene Therapy Treatments GlobeNewswire
Sep-04-19 01:43PM	Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck Business Wire
Aug-23-19 08:30AM	Genprex (GNPX) Featured in Broadcast Discussing Strength, Potential of Biotech Sector GlobeNewswire
Aug-22-19 08:30AM	Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Companys Milestone Achievements GlobeNewswire
Aug-21-19 03:31PM	What Kind Of Investor Owns Most Of Genprex, Inc. (NASDAQ:GNPX)? Simply Wall St.
08:00AM	Genprex to Present at the RHK Capital 4th Annual Disruptive Growth Conference Business Wire
Aug-13-19 08:00AM	Genprex Demonstrates Growth and Expansion Through Recent Achievements Business Wire +7.29%
Aug-06-19 08:00AM	Genprex Manufacturing Partner Aldevron Completes Significant Step in Manufacturing for Oncoprex Clinical Development Program Business Wire -5.85%
Jul-31-19 08:30AM	Genprex Begins Next Phase of Drug Branding Program Business Wire
Jul-09-19 01:58PM	5 Immunotherapy Stocks to Keep a Close Eye On GuruFocus.com
Jul-01-19 08:30AM	Genprex Provides Update on Development of its Oncoprex Immunogene Therapy in Combination with Immunotherapy for Non-Small Cell Lung Cancer Business Wire
May-31-19 08:30AM	Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Gene Therapy as Potential Cancer Treatment GlobeNewswire
May-30-19 08:35AM	Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Hunt for Gene Therapy Breakthroughs GlobeNewswire
May-21-19 08:30AM	Genprex to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum Business Wire
May-09-19 08:30AM	Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Promising New Gene Therapies GlobeNewswire
May-08-19 08:30AM	Genprex Retains Addison Whitney for Drug Nomenclature Branding Business Wire
08:30AM	Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Gene Therapies for Cancer Treatment GlobeNewswire
Apr-12-19 09:00AM	Genprex Featured in NetworkNewsAudio Broadcast on Potential Gene Therapy Treatment for Cancer Newsfile
09:00AM	Genprex (GNPX) Featured in NetworkNewsAudio Broadcast Discussing Gene Therapy Programs on the Cusp of Curing the Incurable GlobeNewswire
Apr-11-19 08:30AM	Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Cancer and Gene Therapy Treatment GlobeNewswire
08:30AM	Genprex (GNPX) Featured in NetworkNewsWire Publication about Revolutionary Gene Therapies Newsfile
Apr-08-19 08:30AM	Genprex Collaborators Report Positive TUSC2 and Checkpoint Blockade Preclinical Data at the 2019 AACR Annual Meeting Business Wire
Apr-01-19 08:30AM	Genprex Provides Clinical, Corporate, and Financial Update for the Year Ending December 31, 2018 Business Wire +5.79%
Mar-29-19 09:00AM	Genprex Featured in NetworkNewsAudio Publication on Unprecedented Targeting in Cancer Treatment Newsfile -6.23%
09:00AM	Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Advanced Medical Cancer Therapy GlobeNewswire
Mar-28-19 08:30AM	Genprex Featured in NetworkNewsWire Publication on Innovations in Cancer Therapy Newsfile
08:30AM	Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Innovative Cancer Treatments GlobeNewswire

Genprex, Inc. operates as a clinical-stage gene therapy company that develops therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes. It develops drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company's lead product candidate REQORSA (quaratusugene ozeplasmid) for treatment for non-small cell lung cancer (NSCLC) has a multimodal mechanism of action to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis and programmed cell death in cancer cells; modulate immune response against cancer cells; and block mechanisms that create drug resistance. Genprex, Inc. was founded in 2009 and is headquartered in Austin, Texas.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience